Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial
Journal of the American Heart Association · 05.08.2025 · 14 (15)
DOI: 10.1161/jaha.124.040327 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 05.08.2025. Verfasst von Robert F Storey und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine University of Sheffield United Kingdom. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type‐2 diabetes (T2DM) in the DAPA‐MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post–myocardial infarction requires elucidation.
Methods
Participants with T2DM diagnosis, without baseline hemoglobin A1c , or not receiving any study medication, were excluded. Eligible participants were categorized, according to baseline hemoglobin A1c , as normoglycemic (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Medicine University of Sheffield United Kingdom.
- NIHR Sheffield Biomedical Research Centre Sheffield Teaching Hospitals NHS Foundation Trust Sheffield United Kingdom.
- Institute of Cardiovascular Sciences, University College London London United Kingdom.
- Uppsala Clinical Research Center, Uppsala University Uppsala Sweden.
- Department of Medical Sciences, Cardiology Uppsala University Sweden.
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds United Kingdom.
ORCID-Profile: Robert F Storey, Stefan James, Ramzi A Ajjan, Niclas Eriksson, David Erlinge, Mark de Belder, Chris P Gale, Azfar Zaman, Robin Hofmann, Linda Mellbin, Kasper Andersen, Anna Maria Langkilde, Jonas Oldgren, Darren K McGuire
Zitieren
APA
Storey, R. F., Deanfield, J., James, S., Ajjan, R. A., Eriksson, N., Erlinge, D., de Belder, M., Gale, C. P., Zaman, A., Hofmann, R., Mellbin, L., Andersen, K., Jiang, Y., Johansson, P. A., Ridderstråle, W., Langkilde, A. M., Parvaresh Rizi, E., Oldgren, J., & McGuire, D. K. (2025). Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial. Journal of the American Heart Association, 14(15). https://doi.org/10.1161/jaha.124.040327
Vancouver
Storey RF, Deanfield J, James S, Ajjan RA, Eriksson N, Erlinge D, et al. Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial. Journal of the American Heart Association. 2025;14(15). doi:10.1161/jaha.124.040327
BibTeX
@article{Storey2025,
author = {Storey, Robert F and Deanfield, John and James, Stefan and Ajjan, Ramzi A and Eriksson, Niclas and Erlinge, David and de Belder, Mark and Gale, Chris P and Zaman, Azfar and Hofmann, Robin and Mellbin, Linda and Andersen, Kasper and Jiang, Yunyun and Johansson, Peter A and Ridderstråle, Wilhelm and Langkilde, Anna Maria and Parvaresh Rizi, Ehsan and Oldgren, Jonas and McGuire, Darren K},
title = {Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA‐MI Trial},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {15},
doi = {10.1161/jaha.124.040327}
}
EUVIMED